Medical Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia

European Urology, Supplements

Volumn 8, Issue 6, 2009, Pages 496-503

  Michel, Martin ^a   de la Rosette, Jean ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Alfuzosin; Disease progression; Doxazosin; Dutasteride; Finasteride; Symptom reduction; Tamsulosin; Terazosin

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; NAFTOPIDIL; PHENOXYBENZAMINE; PHOSPHODIESTERASE INHIBITOR; PRAZOSIN; PROSTATE SPECIFIC ANTIGEN; SILDENAFIL; SILODOSIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TADALAFIL; TAMSULOSIN; TERAZOSIN; VARDENAFIL;

ANEJACULATION; ASTHENIA; BLOOD PRESSURE; CLINICAL TRIAL; DISEASE COURSE; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION; EJACULATION DISORDER; ERECTILE DYSFUNCTION; EYE DISEASE; HUMAN; INTRAOPERATIVE FLOPPY IRIS SYNDROME; LIBIDO; LOWER URINARY TRACT SYMPTOM; ORTHOSTATIC HYPOTENSION; OVERACTIVE BLADDER; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RETROGRADE EJACULATION; REVIEW; SEXUAL FUNCTION; SIDE EFFECT; SURGICAL TECHNIQUE; TRANSURETHRAL RESECTION; UNSPECIFIED SIDE EFFECT; VASODILATATION;

EID: 60449116045     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2009.02.001     Document Type: Review

References (28)

1. 1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance?. Neurourol Urodyn 27 (2008) 226-230
2. Kaplan S.A., Roehrborn C.G., Rovner E.S., Carlsson M., Bavendamm T., and Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. A randomized controlled trial. JAMA 296 (2006) 2319-2328
3. McConnell J.D., Roehrborn C.G., Bautista O., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387-2398
4. Roehrborn C.G., Siami P., Barkin J., et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 179 (2008) 616-621
5. Andersson K.-E., Ückert S., Stief C., and Hedlund P. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. Neurourol Urodyn 26 (2007) 928-933
6. Michel M.C., and Goepel M. Treatment satisfaction of patients with lower urinary tract symptoms: randomised controlled trials vs. real life practice. Eur Urol 38 Suppl 1 (2000) 40-47
7. 2- and β-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 147 (2006) S88-S119
8. Kortmann B.B.M., Floratos D.L., Kiemeney L.A.L.M., Wijkstra H., and de la Rosette J.J.M.C.H. Urodynamic effects of alpha-adrenoceptor blockers: a review of clinical trials. Urology 62 (2003) 1-9
9. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 64 (2004) 1081-1088
10. Nickel J.C., Sander S., and Moon T.D. A meta-analysis of the vascular-related safety profile and efficacy of α-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract 62 (2008) 1547-1559
11. Michel M.C., Mehlburger L., Bressel H.-U., and Goepel M. Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms. Prostate Cancer Prost Dis 1 (1998) 332-335
12. 1-blocker alfuzosin does not affect total or transition zone volume of the prostate. Prostate Cancer Prostatic Dis 9 (2006) 121-125
13. De la Rosette J.J.M.C.H., Kortmann B.B., Rossi C., Sonke G.S., Floratos D.L., and Kiemeney L.A. Long-term risk of re-treatment of patients using α-blockers for lower urinary tract symptoms. J Urol 167 (2002) 1734-1739
14. Barendrecht M.M., Koopmans R.P., de la Rosette J.J.M.C.H., and Michel M.C. Treatment for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. BJU Int 95 Suppl 4 (2005) 19-28
15. Chang D.F., and Campbell J.R. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 31 (2005) 664-673
16. 1-adrenoceptor antagonists on pupil diameter and urethral tone in rabbits. Naunyn-Schmiedeberg's Arch Pharmacol 372 (2006) 346-353
17. 1-adrenoceptor antagonists on male sexual function. Drugs 66 (2006) 287-301
18. 1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: a results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 98 (2006) 1019-1024
19. Andriole G., Bruchovsky N., Chung L.W.K., et al. Dihydrotestosterone and the prostate: the scientific rationale for 5α-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 172 (2004) 1399-1403
20. Naslund M.J., and Miner M. A review of the clinical efficacy and safety of 5α-reductase inhibitors for the enlarged prostate. Clin Ther 29 (2007) 17-25
21. Boyle P., Gould A.L., and Roehrborn C.G. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 48 (1996) 398-405
22. McConnell J.D., Bruskewitz R., Walsh P., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338 (1998) 557-563
23. Roehrborn C.G. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int 101 Suppl 3 (2008) 17-21
24. Donohue J.F., Sharma H., Abraham R., Natalwala S., Thomas D.R., and Foster M.C. Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of the role of finasteride for decreasing operative blood loss. J Urol 168 (2002) 2024-2026
25. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
26. Michel M.C., and Goepel M. Lower urinary tract symptoms suggestive of benign prostatic obstruction - what's the long-term effectiveness of medical therapies?. Eur Urol 39 Suppl 3 (2001) 20-25
27. Andersson K.-E. LUTS treatment: future treatment options. Neurourol Urodyn 26 (2007) 934-947
28. Lee K.-S., Lee H.W., and Han D.H. Does anticholinergic medication have a role in treating men with overactive bladder and benign prostatic hyperplasia?. Naunyn-Schmiedeberg's Arch Pharmacol 377 (2008) 491-501